|
|
Vaccine Detail
|
mRNA neoantigen tumor vaccine |
| Vaccine Information |
- Vaccine Name: mRNA neoantigen tumor vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: mRNA
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: neoantigen (NCT05227378; NCT03468244; NCT05359354)
- Immunization Route: subcutaneous injection
- Description: Personalized mRNA neoantigen tumor vaccine with or without PD-1/L1 may help treat patients with advanced gastric cancer. (NCT05227378) A personalized mRNA tumor vaccine encoding neoantigen may also help treat patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma. (NCT03468244) The vaccine can also be used in combination with PD-1 for the treatment of advanced solid tumors. (NCT05359354)
|
| Host Response |
|
|
| References |
NCT03468244: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms [https://clinicaltrials.gov/study/NCT03468244]
NCT05227378: Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer [https://clinicaltrials.gov/study/NCT05227378]
NCT05359354: Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT05359354]
|
|
